Verici Dx Expands Scientific Advisory Board

New experts join four current advisors, bringing together leading voices across transplant medicine, surgery, and data science

Franklin, TN – July 23, 2026 – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced an expansion of its Scientific Advisory Board (SAB), appointing 14 new members who will join four current advisors. The new SAB members represent exceptional breadth and depth of expertise across nephrology, transplant surgery, pathology, immunology, and biostatistics. Together with existing Board members, they form a group of highly respected leaders in the transplant community known for generating rigorous, high-quality scientific evidence and shaping clinical practice. The SAB will continue to be chaired by Lorenzo Gallon, MD, Professor of Medicine and Surgery and Director of the Abdominal Organ Transplant Program at the University of Illinois School of Medicine.

This distinguished and influential group reflects Verici Dx’s commitment to advancing innovative, validated solutions designed to improve transplant outcomes.

“The addition of these distinguished experts, spanning clinicians, surgeons, and data scientists, brings an exceptional level of insight and real-world experience,” said Dr. Gallon. “Their collective expertise will be instrumental in guiding Verici’s scientific strategy, supporting ongoing clinical development, and accelerating the adoption of precision diagnostics in transplant care.”

Among the newly appointed members is Henry Randall, MD, a highly regarded transplant surgeon and incoming President of the American Society of Transplant Surgeons, widely recognized for his leadership in applying artificial intelligence in transplantation. His appointment highlights strong endorsement from the surgical community and reinforces the clinical relevance of Verici Dx’s technology.

Newly appointed SAB members include:

• Prince Mohan Anand, MD, FACP, FASN, FAST – Director of Transplant Services, MUSC Health
• Oriol Bestard, MD, PhD – Chief of Nephrology, Vall d’Hebron University Hospital; Research Lead, VHIR
• Antony Chang, MD – Professor, Department of Pathology, University of Chicago
• Aravind Cherukuri, MBBS, PhD, MRCP – Assistant Professor, University of Pittsburgh; Co-Director for Clinical Research, Thomas E. Starzl Transplantation Institute
• Paolo Cravedi, MD, PhD – Associate Professor and Director, Translational Transplant Research Center
• Zahraa Hajjiri, MD – Associate Professor of Clinical Medicine, Medical Director, Transplant Department of Medicine, Division of Nephrology, University of Illinois School of Medicine
• Roslyn B. Mannon, MD, FASN – Professor, University of Nebraska Medical Center; Vice-Chair for Research
• Maarten Naesens, MD, PhD – Transplant nephrologist, University Hospitals Leuven
• Rainer Oberbauer, MD – Director, Department of Nephrology & Dialysis and Transplant Medicine, Medical University of Vienna
• Henry Randall, MD – Executive Director, SSM Health Center for Abdominal Transplantation; Incoming President, ASTS
• Jesse Schold, PhD, M.Stat, M.Ed – Professor, University of Colorado; Director, Center for Outcomes Research and Policy
• Neeraj Singh, MD, FACS, FASRS – Professor and Medical Director, Rutgers Health / Robert Wood Johnson University
• Flavio G. Vincenti, MD – Clinical Professor of Medicine and Surgery, University of California, San Francisco
• Alex Wiseman, MD, FAST – Executive Director of Kidney Transplantation, AdventHealth Transplant, Denver, Colorado

Continuing SAB members include Madhav C. Menon, MD, Yale University; Philip O’Connell, PhD, University of Sydney; Emilio Poggio, MD, Cleveland Clinic; and Weija Zhang, PhD, Albert Einstein College of Medicine.

“We are honored to welcome such an accomplished and diverse group of scientific advisors,” said Sara Barrington, Chief Executive Officer of Verici Dx. “Their leadership and active engagement, particularly among physicians already integrating advanced biomarkers into clinical practice, reflect strong confidence in our approach and tremendous optimism about the future of transplant diagnostics.”

About Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia^®, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.